COOKE MICHAEL P. 4
4 · Magenta Therapeutics, Inc. · Filed Jun 27, 2018
Insider Transaction Report
Form 4
COOKE MICHAEL P.
Chief Scientific Officer
Transactions
- Conversion
Series A Preferred Stock
2018-06-25−10,005→ 0 total→ Common Stock (3,872 underlying) - Conversion
Series B Preferred Stock
2018-06-25−1,287→ 0 total→ Common Stock (498 underlying) - Conversion
Common Stock
2018-06-25+4,370→ 293,023 total
Footnotes (1)
- [F1]The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.